- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 22.03. | Instil Bio Non-GAAP EPS of -$1.26 beats by $2.14 | 3 | Seeking Alpha | ||
| 21.03. | Instil Bio, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
| 21.03. | Instil Bio, Inc. - 10-K, Annual Report | 2 | SEC Filings | ||
| 21.03. | Instil Bio, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 21.03. | Instil Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update | 83 | GlobeNewswire (Europe) | DALLAS, March 21, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. ("Instil") (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today reported... ► Artikel lesen | |
| 17.01. | Instil Bio hits four-month high on rising volumes | 3 | Seeking Alpha | ||
| 16.01. | Instil Bio, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 16.01. | Instil Bio Announces Strategic Update | 218 | GlobeNewswire (Europe) | DALLAS, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. ("Instil" or the "Company") (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte... ► Artikel lesen | |
| 08.12.23 | Instil Bio, Inc. - 8-K, Current Report | 4 | SEC Filings | ||
| 05.12.23 | Instil Bio Announces Effective Date of 1-for-20 Reverse Stock Split | 263 | GlobeNewswire (Europe) | DALLAS, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Instil Bio, Inc. ("Instil" or the "Company") (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte... ► Artikel lesen | |
| 27.11.23 | Instil Bio, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 14.11.23 | Instil Bio Non-GAAP EPS of -$0.16 misses by $0.01 | 3 | Seeking Alpha | ||
| 14.11.23 | Instil Bio Inc reports results for the quarter ended in September - Earnings Summary | 2 | Reuters | ||
| 13.11.23 | Instil Bio, Inc. - 10-Q/A, Quarterly Report | 1 | SEC Filings | ||
| 13.11.23 | Instil Bio Reports Third Quarter 2023 Financial Results and Provides Corporate Update | 154 | GlobeNewswire (Europe) | DALLAS, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Instil Bio, Inc. ("Instil") (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies... ► Artikel lesen | |
| 13.11.23 | Instil Bio, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 13.11.23 | Instil Bio, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 06.11.23 | Instil Bio Announces Poster Presentations of ITIL-306 Preclinical Data at SITC 2023 Annual Meeting | 2 | GlobeNewswire (USA) | ||
| 14.08.23 | Instil Bio Reports Second Quarter 2023 Financial Results and Provides Corporate Update | 199 | GlobeNewswire (Europe) | ITIL-306, first CoStAR-TIL in clinical development, anticipated to start clinical trial ITIL-306-202 in 2H 2023 Initial data from ITIL-306-202 clinical trial anticipated in 2024 ITIL-306 operational... ► Artikel lesen | |
| 11.05.23 | Instil Bio Reports First Quarter 2023 Financial Results and Provides Corporate Update | 214 | GlobeNewswire (Europe) | ITIL-306 phase 1 study anticipated to receive CTA clearance from UK MHRA in 2H'2023 Anticipate initial clinical data from ITIL-306 phase 1 program in 2024 Cash runway beyond 2026 DALLAS, May 11, 2023... ► Artikel lesen |
20 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 13,210 | -0,15 % | Evotec Aktie: Turnaround-Phantasie "zerplatzt" - neue Baissetiefs im Anmarsch? | Neben der Evotec Aktie hatten gestern einige Titel an der Börse unter den höher als erwartet US-Inflationsdaten zu leiden. Für den Aktienkurs des Hamburger Biotech-Unternehmens ging es vor allem am... ► Artikel lesen | |
| MORPHOSYS | 67,70 | 0,00 % | Morphosys: Stellungnahme zur Novarits-Offerte | Vor rund zwei Monaten wird bekannt, dass Novartis Morphosys übernehmen will. Geboten werden 68,00 Euro je Aktie. Das entspricht einem Eigenkapitalwert von 2,7 Milliarden Euro. Die Offerte entspricht... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 1,704 | -3,84 % | Palatin Technologies And 2 Other Stocks Under $3 Insiders Are Buying | ||
| SANGAMO THERAPEUTICS | 0,494 | +1,88 % | Sangamo Therapeutics, Inc.: Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct Offering | Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that it has entered into a securities purchase agreement with institutional investors, providing for the purchase... ► Artikel lesen | |
| INFLARX | 1,235 | +3,87 % | InflaRx: Bis 2026 durchfinanziert - Verlust gestiegen | Das Biotech-Unternehmen InflaRx meldet für das Geschäftsjahr 2023 einen Anstieg des Defizits vor Zinsen und Steuern von 32,2 Millionen Euro auf 44,9 Millionen Euro. Unter dem Strich steigt der Verlust... ► Artikel lesen | |
| TREVENA | 0,341 | +0,44 % | Trevena, Inc.: Trevena Awarded OLINVYK Agreement with Premier, Inc. | CHESTERBROOK, Pa., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Trevena Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with... ► Artikel lesen | |
| AFFIMED | 4,855 | -1,72 % | Affimed N.V.: Affimed Reports 2023 Financial Results and Operational Progress | AFM24 combination with atezolizumab (AFM24-102): Follow-up of the Phase 1/2a combination study confirmed four responses in the non-small cell cancer (NSCLC) EGFR-wildtype cohort: one complete response... ► Artikel lesen | |
| GALAPAGOS NV | 27,440 | +0,15 % | Galapagos NV: Galapagos showcases innovative approach in hematological cancer care with clinical and translational data presentations at EBMT congress 2024 | Two oral presentations and one poster on encore preliminary data from Phase 1/2 CD19 CAR-T studies in non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL) / Richter transformation (RT)
Mechelen... ► Artikel lesen | |
| GINKGO BIOWORKS | 0,872 | 0,00 % | Il Granaio delle Idee and Ginkgo Bioworks Announce Strategic Collaboration to Optimize Sourdough Strains for Bakery Products | IGDI will leverage Ginkgo's Adaptive Laboratory Evolution technology to improve its sourdough starter culture product PADUA, Italy and BOSTON, April 16, 2024 /PRNewswire/ -- Il Granaio delle Idee... ► Artikel lesen | |
| PHIO PHARMACEUTICALS | 0,649 | 0,00 % | Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces Upcoming Presentations at the 81st Annual Meeting of the Society for Investigative Dermatology (SID) | MARLBOROUGH, Mass., April 16, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL siRNA gene silencing technology is... ► Artikel lesen | |
| IMMUNITYBIO | 4,651 | -5,56 % | ImmunityBio files automatic mixed shelf | ||
| EMERGENT BIOSOLUTIONS | 1,809 | +1,32 % | Emergent BioSolutions Reports Fourth Quarter 2023 Financial Results | Fourth Quarter 2023 Total Revenues of $277 million, which aligned our Full Year to the mid-point of guidanceFull Year 2023 Total Revenues of $1.05 billion, which was the mid-point of guidanceFourth... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 3,000 | -0,66 % | Cellectar Biosciences Reports Financial Results for Year Ended 2023 and Provides a Corporate Update | FLORHAM PARK, N.J., March 27, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization... ► Artikel lesen | |
| BIOXCEL THERAPEUTICS | 2,464 | +1,90 % | BioXcel Therapeutics Announces TRANQUILITY In-Care Pivotal Phase 3 Trial Plan With BXCL501 for Agitation Associated With Alzheimer's Dementia | Company plans to initiate trial following recent meeting with FDA No FDA-approved therapies for acute treatment of AAD are currently available NEW HAVEN, Conn., April 10, 2024 (GLOBE NEWSWIRE) --... ► Artikel lesen | |
| OCULAR THERAPEUTIX | 7,364 | +3,60 % | ENPH, OCUL and ITCI are among after hour movers |
Das Unternehmen INSTIL BIO INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,040 (-0,39 %) liegt der Kurs bei 10,290 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
